Grail Inc (GRAL) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-2.46, surpassing Wall Street's consensus estimate of $-3.59 by $1.13. While revenue remained at $0.0B, it matched analyst expectations.
This update provides insight into Grail Inc's operational performance, particularly as the company focuses on early cancer detection technologies. Headquartered in Menlo Park, California, Grail operates as a commercial-stage healthcare company, employing around 1,000 people. Its flagship product, the Galleri test, is designed for the early detection of multiple cancer types, potentially improving treatment outcomes by identifying cancers before symptoms arise.
The company will host an earnings conference call to discuss these results further and provide additional commentary on its business performance. Investors may want to review the full earnings release for complete context on the quarter's results and future outlook.
Upcoming earnings are scheduled for August 10, 2026, with analysts estimating an EPS of $-3.31 and revenue of $44.6M, followed by a second quarter report on May 11, 2026, with an EPS estimate of $-3.44 and revenue of $40.4M.